51
|
Fabricius D, O'Dorisio MS, Blackwell S, Jahrsdörfer B. Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide. J Immunol 2006; 177:5920-7. [PMID: 17056516 DOI: 10.4049/jimmunol.177.9.5920] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Plasmacytoid dendritic cells (PDC) are considered the main sentinels against viral infections and play a major role in immune tolerance. Vasoactive intestinal peptide (VIP) is a potent immunomodulator, whose role in PDC function is unknown. The present study was designed to investigate whether human PDC express VIP receptors and whether VIP has immunological effects on PDC. Using real-time RT-PCR and immunofluorescence, we demonstrated that VIP receptors VPAC1 and VPAC2 are expressed on PDC. After culturing PDC with VIP and CpG oligodeoxynucleotides for 48 h, expression of surface molecules with significance for PDC-T cell interactions as well as IFN-alpha secretion were quantified using FACS analysis and ELISA, respectively. For functional assays, CFSE-stained CD4+ T cells were coincubated with differentially treated PDC. T cell proliferation and production of various cytokines were determined by FACS analysis and ELISA. VIP enhanced PDC expression of CD86, MHC II, and CCR7. In contrast, VIP inhibited PDC secretion of IFN-alpha and expression of Neuropilin-1 and MHC I. The potential of CpG oligodeoxynucleotide-activated PDC to induce proliferation of allogeneic CD4(+) T cells was impaired when VIP was present during activation. Furthermore, pretreatment of PDC with VIP resulted in a decrease of the IFN-gamma:IL-4 ratio in cocultured T cells, suggesting a modulation of the immune response toward Th2. Taken together, these results strongly suggest that VIP regulates the immunological function of human PDC. VIP may thus be involved in the modulation of immune responses to viral infections as well as in the maintenance of immune tolerance.
Collapse
MESH Headings
- CD4-Positive T-Lymphocytes/immunology
- Cell Proliferation
- Cells, Cultured
- Dendritic Cells/chemistry
- Dendritic Cells/drug effects
- Dendritic Cells/immunology
- Humans
- Interferon-alpha/antagonists & inhibitors
- Interferon-alpha/metabolism
- Interferon-gamma/metabolism
- Interleukin-4/metabolism
- Oligodeoxyribonucleotides/pharmacology
- RNA, Messenger/analysis
- RNA, Messenger/metabolism
- Receptors, Vasoactive Intestinal Peptide, Type II/analysis
- Receptors, Vasoactive Intestinal Peptide, Type II/genetics
- Receptors, Vasoactive Intestinal Peptide, Type II/metabolism
- Receptors, Vasoactive Intestinal Polypeptide, Type I/analysis
- Receptors, Vasoactive Intestinal Polypeptide, Type I/genetics
- Receptors, Vasoactive Intestinal Polypeptide, Type I/metabolism
- Transforming Growth Factor beta/metabolism
- Vasoactive Intestinal Peptide/pharmacology
Collapse
Affiliation(s)
- Dorit Fabricius
- Department of Pediatrics, Holden Comprehensive Cancer Center, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
| | | | | | | |
Collapse
|
52
|
Jahrsdörfer B, Blackwell SE, Wooldridge JE, Huang J, Andreski MW, Jacobus LS, Taylor CM, Weiner GJ. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006; 108:2712-9. [PMID: 16809616 PMCID: PMC1895576 DOI: 10.1182/blood-2006-03-014001] [Citation(s) in RCA: 105] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
B cells currently are not viewed as being capable of producing granzyme B or being cytotoxic. We found that B-chronic lymphocytic leukemia (B-CLL) cells treated with interleukin-21 (IL-21) produce low levels of granzyme B. The addition of either CpG oligodeoxynucleotide (ODN) or anti-B-cell-receptor antibody (anti-BCR) to IL-21 results in enhanced production of functional granzyme B by B-CLL cells. B-CLL cells treated with IL-21 and CpG ODN undergo apoptosis and are able to induce apoptosis of untreated bystander B-CLL cells. This effect can be inhibited by anti-granzyme B antibody. Benign human B cells, Epstein-Barr virus (EBV)-transformed lymphoblasts, and many standard lymphoma cell lines produce high levels of granzyme B in response to IL-21 and anti-BCR. Our results suggest that the ability to induce production of functional granzyme B by B cells could open new approaches to the therapy of B-CLL and other B-cell malignancies. Our findings also have significant implications for our understanding of the role of B cells for immune regulation and for a variety of immune phenomena, including cancer immunity, autoimmunity, and infectious immunity.
Collapse
MESH Headings
- Apoptosis/drug effects
- B-Lymphocytes/drug effects
- B-Lymphocytes/enzymology
- B-Lymphocytes/immunology
- Cells, Cultured
- Granzymes
- Humans
- In Vitro Techniques
- Interleukin-21 Receptor alpha Subunit
- Interleukins/pharmacology
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/enzymology
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Lymphocyte Activation/drug effects
- Lysosomal-Associated Membrane Protein 1/metabolism
- Oligodeoxyribonucleotides/pharmacology
- Receptors, Interleukin/genetics
- Receptors, Interleukin-21
- Recombinant Proteins/pharmacology
- Serine Endopeptidases/biosynthesis
- T-Lymphocytes, Cytotoxic/drug effects
- T-Lymphocytes, Cytotoxic/enzymology
- T-Lymphocytes, Cytotoxic/immunology
- Tumor Cells, Cultured
- Up-Regulation/drug effects
Collapse
Affiliation(s)
- Bernd Jahrsdörfer
- Holden Cancer Center at the University of Iowa, 5970Z JPP, University of Iowa, Iowa City, IA 52242, USA
| | | | | | | | | | | | | | | |
Collapse
|
53
|
Jahrsdörfer B, Blackwell SE, Wooldridge JE, Taylor CM, Weiner GJ. Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic leukemia. Oligonucleotides 2005; 15:51-9. [PMID: 15788900 DOI: 10.1089/oli.2005.15.51] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Immunostimulatory CpG-containing oligodeoxynucleotides (CpG ODN) have a number of effects on B cells, including upregulation of immunogenic molecules, and, therefore, appear attractive as potential components of immunotherapy for B cell chronic lymphocytic leukemia (B-CLL). Previous in vitro studies investigating the effect of CpG ODN on B-CLL cells used serum-low conditions and did not account for the longer-half life of CpG ODN in vitro. The present study was designed to explore how the presence of serum and exposure time affect CpG ODN-mediated changes on B-CLL cells. The optimal concentration for CpG ODN-mediated effects in the presence of 100% serum or plasma was higher (10-20 microg/ml) than for serum-low conditions. Maximal CpG ODN-mediated effects required the presence of ODN for no longer than 3 hours. The inhibition of CpG ODN-mediated effects by serum correlated with lower uptake of ODN into B-CLL cells in the presence of serum. A threshold effect on biologic response was observed, with a given amount of ODN internalized, resulting in phenotypic changes. In conclusion, systemic short-term application of CpG ODN appears to be sufficient to induce phenotypic changes, but higher doses of CpG ODN than previously thought may be necessary because of inhibition of their uptake by serum.
Collapse
Affiliation(s)
- Bernd Jahrsdörfer
- The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
| | | | | | | | | |
Collapse
|
54
|
Jahrsdörfer B, Blackwell SE, Weiner GJ. Phosphorothyoate oligodeoxynucleotides block nonspecific binding of Cy5 conjugates to monocytes. J Immunol Methods 2005; 297:259-63. [PMID: 15777948 DOI: 10.1016/j.jim.2004.11.023] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2004] [Revised: 11/18/2004] [Accepted: 11/18/2004] [Indexed: 11/26/2022]
Abstract
Cy5-based monoclonal antibody conjugates, including those containing PE-Cy5 and Cy5 alone, are used widely for multi-color flow cytometry in both research and clinical applications. One problem with these conjugates is they bind to monocytes and macrophages irrespective of antibody specificity. This effect, which is thought to be due to binding of the Cy5 itself to the human high affinity receptor for IgG (FcgammaRI, CD64), can complicate interpretion of flow cytometric results. In the present study we demonstrate that phosphorothioate oligodeoxynucleotides (PS-ODN) suppress this nonspecific binding in a manner that is independent of PS-ODN sequence. Binding of FITC-labeled PS-ODN to monocytes was blocked by CD64-specific monoclonal antibodies, suggesting CD64 is a PS-ODN-binding protein. We conclude PS-ODN can be used as an effective, simple and low-priced reagent to prevent nonspecific binding of Cy5-based immunoconjugates to monocytes. This effect appears to be mediated by PS-ODN binding to CD64 thereby blocking the binding of Cy5 to this receptor.
Collapse
Affiliation(s)
- Bernd Jahrsdörfer
- Holden Comprehensive Cancer Center, Department of Internal Medicine, University of Iowa, 5970Z JPP, Iowa City, IA 52242, USA
| | | | | |
Collapse
|
55
|
Jahrsdörfer B, Wooldridge JE, Blackwell SE, Taylor CM, Link BK, Weiner GJ. Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity. Leukemia 2005; 19:759-66. [PMID: 15759034 DOI: 10.1038/sj.leu.2403694] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Chromosomal abnormalities in B-cell chronic lymphocytic leukemia (B-CLL) have been shown to correlate with prognosis. Little is known about the relationship between chromosomal abnormalities and biological behavior of B-CLL cells in vitro. The present study was designed to explore the impact of chromosomal abnormalities determined by interphase fluorescence in situ hybridization (FISH) on the in vitro survival and immunogenicity of B-CLL. Considerable heterogeneity was noted in the in vitro survival and expression of costimulatory, adhesion, and antigen-presenting molecules by B-CLL cells. Spontaneous apoptosis of B-CLL cells in vitro was significantly lower in samples with good prognosis cytogenetics when compared to samples with poor prognosis cytogenetics. In contrast, B-CLL cells from samples with good prognosis cytogenetics exhibited higher basal expression of molecules involved in costimulation, cellular adhesion, and antigen presentation, and induced significantly more T-cell proliferation in mixed lymphocyte cultures. We conclude that chromosomal aberrations of B-CLL cells correlate with the in vitro biological behavior of B-CLL. Our data indicate that good prognosis cytogenetics correlates with less spontaneous apoptosis but greater in vitro immunogenicity. These findings could have significant implications on the design of future therapeutic approaches in patients with CLL, and the likelihood of response based on cytogenetics.
Collapse
Affiliation(s)
- B Jahrsdörfer
- Department of Internal Medicine, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
| | | | | | | | | | | |
Collapse
|
56
|
Jahrsdörfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK, Weiner GJ. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2004; 77:378-87. [PMID: 15582984 DOI: 10.1189/jlb.0604373] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Immunostimulatory oligodeoxynucleotides (IS ODN) can mediate a number of immunologic effects. We previously demonstrated that treatment of B cell chronic lymphocytic leukemia (B-CLL) cells with one class of IS ODN, CpG ODN, alters their phenotype and increases their immunogenicity. Here, we demonstrate that in contrast to the classic understanding of CpG ODN as inhibitors of B cell apoptosis, IS ODN including CpG ODN induce apoptosis in B-CLL cells. It is important that these changes are seen not only with CpG ODN but with ODN that lack the classical CpG motif. B-CLL cells from 20 subjects were treated in vitro with IS ODN for up to 7 days. IS ODN treatment resulted in increased numbers of apoptotic cells in 13 out of 20 B-CLL samples. IS ODN enhanced apoptosis in samples with 13q deletion as a single aberration and had a heterogeneous effect on apoptosis in samples with other aberrations including 17p deletion, 11q deletion, or trisomy 12. Induction of apoptosis did not correlate with expression of the CpG ODN receptor Toll-like receptor 9. Apoptosis was dependent on the activation of caspases and was accompanied by up-regulation of CD95/Fas and its ligand. We conclude that IS ODN including CpG ODN can induce apoptosis of most B-CLL samples. The ability of IS ODN to induce apoptosis differs based on cytogenetic status. Up-regulation of CD95/Fas may play a role in IS ODN-induced apoptosis of B-CLL.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Apoptosis/drug effects
- Apoptosis/immunology
- Apoptosis/physiology
- Caspases/metabolism
- DNA-Binding Proteins/drug effects
- DNA-Binding Proteins/metabolism
- Female
- Humans
- Immunophenotyping
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Ligands
- Male
- Middle Aged
- Oligodeoxyribonucleotides/immunology
- Oligodeoxyribonucleotides/pharmacology
- Receptors, Cell Surface/drug effects
- Receptors, Cell Surface/metabolism
- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Receptors, Tumor Necrosis Factor/metabolism
- Toll-Like Receptor 9
- fas Receptor/metabolism
Collapse
Affiliation(s)
- Bernd Jahrsdörfer
- Holden Comprehensive Cancer Center, 5970Z JPP, The University of Iowa, Iowa City, IA 52242, USA
| | | | | | | | | | | | | |
Collapse
|
57
|
Govekar E, Klemencic J, Kokalj T, Jahrsdörfer B, Muzic P, Grabec I. Characterisation of a laser droplet formation process by acoustic emission. Ultrasonics 2004; 42:99-103. [PMID: 15047268 DOI: 10.1016/j.ultras.2004.01.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
The aim of this article is to describe an application of acoustic emission to characterise a process of laser droplet formation from a metal wire. Laser droplet formation is a crucial process in new laser droplet welding technology, where parts are joined by means of the heat content of a liquid metal droplet deposited onto the parts to be joined. A laser beam is used for heating and melting the wire tip, and for detaching the molten pendant droplet. Depending on the process parameters, three different outcomes of the process can be observed: (1) no droplet formed; (2) a droplet formed but not detached; (3) a droplet formed and detached from the wire. It is shown that AE can be used to monitor the process and to indicate the different process outcomes.
Collapse
Affiliation(s)
- E Govekar
- Faculty of Mechanical Engineering, University of Ljubljana, Slovenia.
| | | | | | | | | | | |
Collapse
|
58
|
Meinhardt G, Dayyani F, Jahrsdörfer B, Baumgart J, Emmerich B, Schmidmaier R. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol 2003; 122:892-9. [PMID: 12956758 DOI: 10.1046/j.1365-2141.2003.04525.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Multiple myeloma is a non-curable haematological disease involving transformed plasma cells. High rates of complete remission can be achieved with autologous peripheral blood stem cell transplantation. Treosulfan is an alkylating substance that has been used in the treatment of ovarian carcinomas for many years. It has a favourable side-effect profile even at high-dose protocols. Thus, the objective of this study was to evaluate the effect of treosulfan on myeloma cells. The treatment of the myeloma cell lines, NCI-H929 and U266, with treosulfan led to apoptosis in both cell lines in a dose- and time-dependent manner. The induction of apoptosis was accompanied by cleavage of caspases -3 and -9 as well as downregulation of the antiapoptotic protein Mcl-1 and upregulation of the inhibitor of cyclin-dependent kinases, p21WAF1/CIP1. Furthermore, 100 micro mol/l treosulfan was capable of inducing cell death in 63.6 +/- 23.9% of primary myeloma cells, whereas treatment with the same concentration of melphalan showed 59.7 +/- 26% cell death. These in vitro concentrations were at least 10-fold lower than achievable plasma levels, even at conventional doses of treosulfan. Our results suggest that treosulfan might be an appropriate candidate for novel treatment protocols for patients with multiple myeloma.
Collapse
Affiliation(s)
- Gerold Meinhardt
- Klinikum der Universität München, Medizinische Klinik - Innenstadt, Department of Hematology/Oncology, Laboratory of Molecular Hematology and Oncology, Munich, Germany.
| | | | | | | | | | | |
Collapse
|
59
|
Abstract
Synthetic oligodeoxynucleotides containing CG motifs (CpG ODN) have potent immunostimulatory properties, and have potential as immunotherapeutic agents in cancer. Animal models suggest CpG ODN can activate a variety of immune effector cells such as natural killer (NK) cells, and also enhance the efficacy of tumor immunization when used as immune adjuvants or to directly activate antigen-presenting cells. CpG ODN are also capable of altering the expression of a number of antigens by malignant B-cells, including those targeted by monoclonal antibodies (moAbs) and those involved in communication with T cells. The ability of CpG ODN to activate the immune effector cells that participate in antibody-dependent cellular cytotoxicity (ADCC), upregulate target antigen, and perhaps induce development of an active immune response, suggest these agents may be capable of enhancing the efficacy of antitumor moAb therapy. Such enhanced efficacy has been demonstrated in animal models and is now undergoing evaluation in clinical trials.
Collapse
Affiliation(s)
- Bernd Jahrsdörfer
- Holden Comprehensive Cancer Center, Department of Internal Medicine, Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, USA
| | | |
Collapse
|
60
|
Jahrsdörfer B, Weiner GJ. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr Opin Investig Drugs 2003; 4:686-90. [PMID: 12901226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
Synthetic oligodeoxynucleotides containing CG motifs (CpG ODNs) have potent immunostimulatory properties, and have potential as immunotherapeutic agents in cancer. Animal models suggest that CpG ODNs may be useful as both single agents and to enhance the efficacy of monoclonal antibody therapy. CpG ODNs can also enhance the efficacy of tumor immunization through use as an immune adjuvant, to activate antigen presenting cells, or as a component of DNA vaccines. Clinical trials are now beginning to assess whether the promise of these agents in the laboratory will translate into CpG ODNs becoming a valuable component of clinical cancer immunotherapy.
Collapse
Affiliation(s)
- Bernd Jahrsdörfer
- Holden Comprehensive Cancer Center, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
| | | |
Collapse
|
61
|
Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdörfer B, Krug A, Rothenfusser S, Endres S, Hartmann G. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002; 169:3892-9. [PMID: 12244187 DOI: 10.4049/jimmunol.169.7.3892] [Citation(s) in RCA: 151] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The immune system of vertebrates is able to detect bacterial DNA based on the presence of unmethylated CpG motifs. We examined the therapeutic potential of oligodeoxynucleotides with CpG motifs (CpG ODN) in a colon carcinoma model in BALB/c mice. Tumors were induced by s.c. injection of syngeneic C26 cells or Renca kidney cancer cells as a control. Injection of CpG ODN alone or in combination with irradiated tumor cells did not protect mice against subsequent tumor challenge. In contrast, weekly injections of CpG ODN into the margin of already established tumors resulted in regression of tumors and complete cure of mice. The injection site was critical, since injection of CpG ODN at distant sites was not effective. Mice with two bilateral C26 tumors rejected both tumors upon peritumoral injection of one tumor, indicating the development of a systemic immune response. The tumor specificity of the immune response was demonstrated in mice bearing a C26 tumor and a Renca tumor at the same time. Mice that rejected a tumor upon peritumoral CpG treatment remained tumor free and were protected against rechallenge with the same tumor cells, but not with the other tumor, demonstrating long term memory. Tumor-specific CD8 T cells as well as innate effector cells contributed to the antitumor activity of treatment. In conclusion, peritumoral CpG ODN monotherapy elicits a strong CD8 T cell response and innate effector mechanisms that seem to act in concert to overcome unresponsiveness of the immune system toward a growing tumor.
Collapse
MESH Headings
- Animals
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/immunology
- CD8-Positive T-Lymphocytes/immunology
- Colonic Neoplasms/drug therapy
- Colonic Neoplasms/immunology
- CpG Islands/immunology
- Cytotoxicity, Immunologic/drug effects
- Cytotoxicity, Immunologic/immunology
- DNA/administration & dosage
- DNA/immunology
- DNA, Neoplasm/administration & dosage
- DNA, Neoplasm/immunology
- Disease Models, Animal
- Immunity, Innate/drug effects
- Immunity, Innate/immunology
- Immunologic Memory/drug effects
- Immunologic Memory/immunology
- Injections, Intralesional
- Injections, Subcutaneous
- Kidney Neoplasms/drug therapy
- Kidney Neoplasms/immunology
- Mice
- Mice, Inbred BALB C
- Oligodeoxyribonucleotides
Collapse
Affiliation(s)
- Klaus Heckelsmiller
- Department of Internal Medicine, Division of Clinical Pharmacology, University of Munich, Munich, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
62
|
Jahrsdörfer B, Jox R, Mühlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G. Modulation of malignant B cell activation and apoptosis by bcl‐2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002. [DOI: 10.1189/jlb.72.1.83] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- B. Jahrsdörfer
- Division of Clinical Pharmacology and Oncology, Department of Internal Medicine, University of Munich, Germany
| | - R. Jox
- Division of Clinical Pharmacology and Oncology, Department of Internal Medicine, University of Munich, Germany
| | - L. Mühlenhoff
- Division of Clinical Pharmacology and Oncology, Department of Internal Medicine, University of Munich, Germany
| | - K. Tschoep
- Division of Clinical Pharmacology and Oncology, Department of Internal Medicine, University of Munich, Germany
| | - A. Krug
- Division of Clinical Pharmacology and Oncology, Department of Internal Medicine, University of Munich, Germany
| | - S. Rothenfusser
- Division of Clinical Pharmacology and Oncology, Department of Internal Medicine, University of Munich, Germany
| | - G. Meinhardt
- Division of Hematology and Oncology, Department of Internal Medicine, University of Munich, Germany
| | - B. Emmerich
- Division of Hematology and Oncology, Department of Internal Medicine, University of Munich, Germany
| | - S. Endres
- Division of Clinical Pharmacology and Oncology, Department of Internal Medicine, University of Munich, Germany
| | - G. Hartmann
- Division of Clinical Pharmacology and Oncology, Department of Internal Medicine, University of Munich, Germany
| |
Collapse
|
63
|
Jahrsdörfer B, Jox R, Mühlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002; 72:83-92. [PMID: 12101266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023] Open
Abstract
Inhibition of bcl-2 expression by antisense oligodeoxynucleotides (ODN) might render bcl-2 overexpressing malignant B cells more susceptible to chemotherapy. ODN containing unmethylated CG dinucleotides (CpG) are known to activate B cells. We studied the effects of two bcl-2 antisense ODN, with (G3139) or without CG dinucleotides (NOV 2009) within the sequence, and the effects of a nonantisense, CpG-containing ODN (ODN 2006) on activation and apoptosis of malignant B cell lines and primary B-CLL cells. Without cationic lipids, no antisense-mediated inhibition of bcl-2 synthesis was achieved with G3139 and NOV 2009. Instead, G3139, but not NOV 2009, induced similar changes as ODN 2006 in proliferation, expression of costimulatory and antigen-presenting molecules, as well as in bcl-2 and bcl-xL levels of primary B-CLL cells. G3139 and ODN 2006 inhibited in vitro, spontaneous apoptosis in B-CLL cells of patients with high serum thymidine kinase activity (s-TK, marker for proliferative activity of malignant B cells), whereas in patients with low s-TK activity, apoptosis was induced. In conclusion, our results suggest that modulation of malignant B cell apoptosis by G3139 depends on its immunostimulatory properties rather than on antisense-mediated reduction of bcl-2 expression. Immunostimulatory CpG ODN may have a therapeutic potential in patients with B-CLL, especially those with low s-TK activity.
Collapse
MESH Headings
- Adjuvants, Immunologic/chemistry
- Adjuvants, Immunologic/pharmacology
- Apoptosis
- Gene Expression Regulation
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Lymphocyte Activation
- Oligodeoxyribonucleotides/chemistry
- Oligodeoxyribonucleotides/pharmacology
- Oligodeoxyribonucleotides, Antisense/pharmacology
- Phosphatidylethanolamines
- Proto-Oncogene Proteins c-bcl-2/biosynthesis
- Proto-Oncogene Proteins c-bcl-2/genetics
- Thymidine Kinase/metabolism
- Tumor Cells, Cultured
- bcl-X Protein
Collapse
Affiliation(s)
- B Jahrsdörfer
- Division of Clinical Pharmacology, Department of Internal Medicine, University of Munich, Ziemssenstrasse 1, 80336 Munich, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
64
|
Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T, Endres S, Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168:4531-7. [PMID: 11970999 DOI: 10.4049/jimmunol.168.9.4531] [Citation(s) in RCA: 1480] [Impact Index Per Article: 67.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The Toll-like receptor (TLR)9 is critical for the recognition of immunostimulatory CpG motifs but may cooperate with other TLRs. We analyzed TLR1-10 mRNA expression by using quantitative real-time PCR in highly purified subsets of human PBMC and determined the sensitivity of these subsets to CpG oligodeoxynucleotides (ODN). TLR1 and TLR6 were expressed in all cell types examined. TLR10 was highly expressed in B cells and weakly expressed in plasmacytoid dendritic cells (PDC). High expression of TLR2 was characteristic for monocytes. PDC and B cells expressed marked levels of TLR7 and TLR9 and were directly sensitive to CpG ODN. In CpG ODN-stimulated PDC and B cells, TLR9 expression rapidly decreased, as opposed to TLR7, which was up-regulated in PDC and decreased in B cells. In monocytes, NK cells, and T cells, TLR7 was absent. Despite low expression of TLR9, monocytes, NK cells, and T cells did not respond to CpG ODN in the absence of PDC but were activated in the presence of PDC. In conclusion, our studies provide evidence that PDC and B cells, but not monocytes, NK cells, or T cells, are primary targets of CpG ODN in peripheral blood. The characteristic expression pattern of TLR1-10 in cellular subsets of human PBMC is consistent with the concept that TLR9 is essential in the recognition of CpG ODN in PDC and B cells. In addition, selective regulation of TLR7 expression in PDC and B cells by CpG ODN revealed TLR7 as a candidate TLR potentially involved in modulating the recognition of CpG motifs.
Collapse
MESH Headings
- Adjuvants, Immunologic/pharmacology
- B-Lymphocytes/drug effects
- B-Lymphocytes/immunology
- Blood/immunology
- Cells, Cultured
- Clone Cells
- DNA-Binding Proteins/biosynthesis
- DNA-Binding Proteins/genetics
- Dendritic Cells/drug effects
- Dendritic Cells/immunology
- Drosophila Proteins
- Gene Expression Regulation
- Humans
- Immunologic Memory
- Killer Cells, Natural/drug effects
- Killer Cells, Natural/immunology
- Kinetics
- Leukocytes, Mononuclear/classification
- Leukocytes, Mononuclear/drug effects
- Leukocytes, Mononuclear/immunology
- Membrane Glycoproteins/biosynthesis
- Membrane Glycoproteins/genetics
- Monocytes/drug effects
- Monocytes/immunology
- Oligodeoxyribonucleotides/pharmacology
- Polymerase Chain Reaction
- Protein Isoforms/biosynthesis
- Protein Isoforms/genetics
- RNA, Messenger/biosynthesis
- Receptors, Cell Surface/biosynthesis
- Receptors, Cell Surface/genetics
- T-Lymphocytes/drug effects
- T-Lymphocytes/immunology
- Toll-Like Receptor 1
- Toll-Like Receptor 10
- Toll-Like Receptor 2
- Toll-Like Receptor 7
- Toll-Like Receptor 9
- Toll-Like Receptors
Collapse
Affiliation(s)
- Veit Hornung
- Department of Internal Medicine, Division of Clinical Pharmacology, University of Munich, Munich, Germany
| | | | | | | | | | | | | | | |
Collapse
|
65
|
Krug A, Rothenfusser S, Hornung V, Jahrsdörfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001. [PMID: 11449369 DOI: 10.1002/1521-4141(200107)31] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The immature plasmacytoid dendritic cell (PDC) is identical with the principal type I IFN-producing cell upon viral infection. Oligodeoxynucleotides which contain unmethylated CpG motifs (CpG ODN) are recognized by the vertebrate immune system. Previously, we described CpG ODN that strongly activate human B cells and human blood dendritic cells. Here we describe distinct CpG-containing oligonucleotide sequences which, in contrast to previously described CpG ODN, induced high amounts of IFN-alpha and IFN-beta in peripheral blood mononuclear cells (PBMC). Intracellular staining for IFN-alpha revealed that within PBMC CpG ODN-induced IFN-alpha is produced exclusively by PDC. Unlike IFN-alpha, TNF-alpha is up-regulated in PDC by all CpG ODN tested. Purified PDC responded to CpG ODN, demonstrating direct activation of PDC by CpG ODN. The most active sequence induced the production of up to 5 pg IFN-alpha per single PDC, resulting in more than 400 ng/ml IFN-alpha in the supernatant of PBMC enriched for PDC. The potency of CpG ODN to stimulate IFN-alpha correlated with their ability to stimulate NK cell lytic activity, while purified NK cells did not respond to CpG ODN. IFNgamma production in PBMC was dependent on CpG ODN-induced IFN-alpha/beta as demonstrated by IFN-alpha/beta blocking antibodies. IFN-alpha-inducing CpG ODN strongly supported IFN-gamma production of TCR-triggered CD4 T cells but were less active than other CpG ODN in stimulating B cells. In conclusion our results demonstrate that particular CpG ODN sequences exist which, due to high IFN-alpha/beta induction in PDC, induce a set of immune responses typical for viral infection.
Collapse
Affiliation(s)
- A Krug
- Department of Internal Medicine, Division of Clinical Pharmacology, University of Munich, Munich, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
66
|
Krug A, Rothenfusser S, Hornung V, Jahrsdörfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001; 31:2154-63. [PMID: 11449369 DOI: 10.1002/1521-4141(200107)31:7<2154::aid-immu2154>3.0.co;2-u] [Citation(s) in RCA: 650] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The immature plasmacytoid dendritic cell (PDC) is identical with the principal type I IFN-producing cell upon viral infection. Oligodeoxynucleotides which contain unmethylated CpG motifs (CpG ODN) are recognized by the vertebrate immune system. Previously, we described CpG ODN that strongly activate human B cells and human blood dendritic cells. Here we describe distinct CpG-containing oligonucleotide sequences which, in contrast to previously described CpG ODN, induced high amounts of IFN-alpha and IFN-beta in peripheral blood mononuclear cells (PBMC). Intracellular staining for IFN-alpha revealed that within PBMC CpG ODN-induced IFN-alpha is produced exclusively by PDC. Unlike IFN-alpha, TNF-alpha is up-regulated in PDC by all CpG ODN tested. Purified PDC responded to CpG ODN, demonstrating direct activation of PDC by CpG ODN. The most active sequence induced the production of up to 5 pg IFN-alpha per single PDC, resulting in more than 400 ng/ml IFN-alpha in the supernatant of PBMC enriched for PDC. The potency of CpG ODN to stimulate IFN-alpha correlated with their ability to stimulate NK cell lytic activity, while purified NK cells did not respond to CpG ODN. IFNgamma production in PBMC was dependent on CpG ODN-induced IFN-alpha/beta as demonstrated by IFN-alpha/beta blocking antibodies. IFN-alpha-inducing CpG ODN strongly supported IFN-gamma production of TCR-triggered CD4 T cells but were less active than other CpG ODN in stimulating B cells. In conclusion our results demonstrate that particular CpG ODN sequences exist which, due to high IFN-alpha/beta induction in PDC, induce a set of immune responses typical for viral infection.
Collapse
Affiliation(s)
- A Krug
- Department of Internal Medicine, Division of Clinical Pharmacology, University of Munich, Munich, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
67
|
Jahrsdörfer B, Hartmann G, Racila E, Jackson W, Mühlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001. [DOI: 10.1189/jlb.69.1.81] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
| | | | - Emil Racila
- the Holden Cancer Center at the University of Iowa, Iowa City, Iowa
| | | | | | - Gerold Meinhardt
- Division of Hematology, Department of Internal Medicine, University of Munich, Germany
| | | | - Brian K. Link
- Department of Internal Medicine, Iowa City, Iowa
- the Holden Cancer Center at the University of Iowa, Iowa City, Iowa
- Coley Pharmaceutical Group Inc., Wellesley, Massachusetts
| | - Arthur M. Krieg
- Department of Internal Medicine, Iowa City, Iowa
- the Holden Cancer Center at the University of Iowa, Iowa City, Iowa
- Coley Pharmaceutical Group Inc., Wellesley, Massachusetts
| | - George J. Weiner
- Department of Internal Medicine, Iowa City, Iowa
- the Holden Cancer Center at the University of Iowa, Iowa City, Iowa
| |
Collapse
|
68
|
Jahrsdörfer B, Hartmann G, Racila E, Jackson W, Mühlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001; 69:81-8. [PMID: 11200072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
Abstract
Multiple factors, including expression of costimulatory molecules, antigen-presenting molecules, and target antigens, likely impact the efficacy of antibody therapy and other approaches to the immunotherapy of B cell malignancy. Unmethylated CpG-dinucleotides in select base contexts ("CpG motifs") that resemble sequences found in bacterial DNA are potent immunostimulatory agents capable of inducing a complex immune response, including a strong B cell stimulus. We examined the effect of a potent human CpG oligonucleotide (CpG ODN 2006) on different types of primary human malignant B cells and reactive follicular hyperplasia. CpG oligodeoxynucleotide (CpG ODN), but not control (non-CpG ODN), increased the expression of costimulatory molecules (CD40, CD80, CD86, CD54) on malignant B cells without altering the phenotype of B cells obtained from reactive follicular hyperplasia. CpG ODN also enhanced expression of class I and class II MHC in most samples. CD20 expression was increased in response to CpG ODN, most notably in B-CLL and marginal zone lymphoma. An inverse correlation was found between baseline expression of CD20 and CD40 and their expression after exposure to CpG ODN, thus the most significant increase in expression of these molecules was found in those samples that had the lowest baseline levels. In conclusion, CpG ODN can lead to increasing expression of molecules involved in costimulation, antigen presentation, and as targets for antibody-based therapy and deserve further evaluation as potential immunotherapeutic agents for B cell malignancy.
Collapse
Affiliation(s)
- B Jahrsdörfer
- Department of Internal Medicine, University of Munich, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
69
|
|